Brevibloc DOUBLE STRENGTH Premixed Injection — Class II drug recall D-0852-2016
Terminated recall by Baxter Healthcare Corp., reported 2016-05-18, distributed nationwide. Discoloration: presence of atypical yellow discoloration of the solution .
| Recall number | D-0852-2016 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Baxter Healthcare Corp., Deerfield, IL, United States |
| Recall initiated | 2016-04-12 |
| Classified | 2016-05-12 |
| Reported by FDA | 2016-05-18 |
| Terminated | 2017-03-20 |
| Distributed | Nationwide (US) |
| Quantity | 11,630 babs |
| NDC | 10019-0055, 10019-0055-61, 10019-0075, 10019-0075-87, 10019-0115, 10019-0115-01, 10019-0115-39 |
| Lot numbers | 9/17, C989954 |
Product
Brevibloc DOUBLE STRENGTH Premixed Injection, Esmolol Hydrochloride in Sodium Chloride, 2000mg/100mL (20 mg/mL), 100 mL, Rx only, Manufactured by Baxter Healthcare Corporation, Deerfield, Il 60015, NDC 10019-075-87
Reason for recall
Discoloration: presence of atypical yellow discoloration of the solution .
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0852-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.